Taisho signs deal with Arena Pharma
Taisho of Japan has entered into a G protein-coupled receptor researchcollaboration with Arena Pharmaceuticals of the USA, which will ultimately focus on the application of the latter firm's CART technology to the receptor. The companies said that, "due to the highly competitive subject matter of the research," the name of the endogenous ligand (which has been identified) has not been revealed. Financial terms of the deal were not disclosed.
Jack Lief, Arena's chief executive, said that the company currently has about half of all human GPCRs at its disposal, therefore the firm believes "that the odds favor finding a GPCR that binds with Taisho's endogenous ligand with the receptors that we have in-house." This latest deal with Arena is Taisho's 11th joint-research alliance, and the firms have collaborated on two previous occasions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze